Metoject — supply status, manufacturers & alternatives

Metoject

—

In supply · Australia

In supply · 🇦🇺 Australia

In supply in Australia

No active shortage reported.

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Registrations on file
Active ingredient (INN)	Metoject
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No
Marketing-authorisation holders	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH, MEDEXUS PHARMACEUTICALS INC.

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇫🇷 FR

€20.29

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 5 resolved events

◷

0–3 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇪🇸

Spain

AEMPS · 2d ago

Resolved

Verified timeline regulator events

🇪🇸 19 May 2026

Shortage resolved

🇪🇸 31 Mar 2026

Shortage resolved

🇪🇸 22 Feb 2026

Shortage resolved

🇪🇸 6 Jan 2026

Shortage resolved

🇪🇸 4 Jan 2026

Shortage resolved

Sources official regulators

🇪🇸

AEMPS

verified 2d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders12 registrations · 2 MA holders

Product	Strength	Form	Market	MA holder	Status
Metoject Pen	7.5 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Pen	10 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Pen	12.5 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Pen	15 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Pen	17.5 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Pen	20 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Pen	22.5 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Pen	25 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Pen	27.5 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Pen	30 MG	injection	🇬🇧 GB	MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH	Active
Metoject Subcutaneous	—	solution	🇨🇦 CA	MEDEXUS PHARMACEUTICALS INC.	Active
METOJECT	—	solution	🇨🇦 CA	MEDEXUS PHARMACEUTICALS INC.	Active

Mederti Drug Report

Generated 4 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.